Allarity names Jeremy Graff as president, CDO, Jose Iglesias as consultant CMO

Allarity Therapeutics (ALLR) announced several key leadership appointments to accelerate its clinical and strategic development. To further advance its clinical development efforts, Allarity has appointed Jeremy R. Graff, Ph.D., as President and Chief Development Officer. Dr. Graff, who has been a consultant to the Company since December 2023, will now take on a more formal leadership role. During his nearly 17-year tenure at Eli Lilly and Company (LLY), Dr. Graff established and led the translational oncology group, advancing 31 clinical assets in the company’s oncology portfolio. In his new role at Allarity, Dr. Graff will continue to oversee the Company’s clinical development programs, including the advancement of its dual PARP and Tankyrase inhibitor, stenoparib, alongside Allarity’s Drug Response Predictor companion diagnostic. Additionally, Allarity announced the appointment of Jose Iglesias, M.D., as Consultant Chief Medical Officer. Dr. Iglesias, with over 35 years of global experience in the pharmaceutical industry, will significantly enhance the Company’s expertise in oncology clinical development. His appointment comes as Allarity accelerates the stenoparib program’s path toward regulatory approval for the treatment of advanced ovarian cancer. His career includes leadership roles at Biothera, Boston Biomedical, Celgene Corporation, and Eli Lilly and Company. In further strengthening its leadership team, Allarity has appointed Jesper Hoiland, the former President of Novo Nordisk’s (NVO) U.S. operations, as a key Strategic Advisor. Mr. Hoiland’s global pharmaceutical leadership experience will be instrumental in advancing the Company’s strategic initiatives, particularly around the anticipated commercialization of stenoparib.